Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 13/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328980 | 0.87 | CDK4 (0.49) | ROCK2ROCK1CDK4CCNA2CCND1 | |
| SCHEMBL4341086 | 0.84 | MAPK1 (0.41) | ROCK2ROCK1CDK4CCNA2CCND1 | |
| SCHEMBL4326727 | 0.84 | TRPV3 (0.47) | MAPK1MAPK3 | |
| SCHEMBL4343384 | 0.83 | MAPK1 (0.39) | ROCK2ROCK1MAPK1MAPK3CNR1 | |
| SCHEMBL5032344 | 0.82 | CNR1 (0.48) | ROCK2ROCK1CDK4CCNA2CCND1 | |
| SCHEMBL4343373 | 0.79 | ROCK2 (0.40) | ROCK2ROCK1CDK4CCNA2CCND1 | |
| SCHEMBL13927653 | 0.79 | CNR1 (0.44) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL2862300 | 0.78 | MEN1 (0.47) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL2867207 | 0.77 | KDR (0.48) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL6427310 | 0.77 | CNR1 (0.44) | MAPK1MAPK3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | ROCK2 805/4885ROCK1 504/4885CDK4 103/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | ROCK2 805/4885ROCK1 504/4885CDK4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.